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Summary 
Background Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective, and new 
more effective and safe strategies are needed. Our aim was to assess the efficacy of oral methylprednisolone as an 
add-on therapy to subcutaneous interferon beta-1a to reduce the yearly relapse rate in patients with relapsing-remitting 
multiple sclerosis. 
Methods NORMIMS (NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment 
of relapsing-remitting Multiple Sclerosis) was a randomised, placebo-controlled trial done in 29 neurology departments 
in Denmark, Norway, Sweden, and Finland. We enrolled outpatients with relapsing-remitting multiple sclerosis who 
had had at least one relapse within the previous 12 months despite subcutaneous interferon beta-1a treatment (44 μg 
three times per week). We randomly allocated patients by computer to add-on therapy of either 200 mg 
methylprednisolone or matching placebo, both given orally on 5 consecutive days every 4 weeks for at least 96 weeks. 
The primary outcome measure was mean yearly relapse rate. Primary analyses were by intention to treat. This trial is 
registered, number ISRCTN16202527. 
Findings 66 patients were assigned to interferon beta and oral methylprednisolone and 64 were assigned to interferon 
beta and placebo. A high proportion of patients withdrew from the study before week 96 (26% [17 of 66] on 
methylprednisolone vs 17% [11 of 64] on placebo). The mean yearly relapse rate was 0·22 for methylprednisolone 
compared with 0·59 for placebo (62% reduction, 95% CI 39–77%; p<0·0001). Sleep disturbance and neurological and 
psychiatric symptoms were the most frequent adverse events recorded in the methylprednisolone group. Bone 
mineral density had not changed after 96 weeks. 
Interpretation Oral methylprednisolone given in pulses every 4 weeks as an add-on therapy to subcutaneous interferon 
beta-1a in patients with relapsing-remitting multiple sclerosis leads to a signifi cant reduction in relapse rate. However, 
because of the small number of patients and the high dropout rate, these fi ndings need to be corroborated in larger 
cohorts. 
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Introduction 
Interferon beta is an effective and safe treatment for 
relapsing-remitting multiple sclerosis.1,2 Similar to other 
treatments for this disorder, interferon beta is only partly 
effective, and second-line therapies with enhanced 
effectiveness are associated with potentially serious 
adverse events.3–6 Thus, new safe and effective regimens 
are needed. 
The findings of previous studies suggest that 
methylprednisolone might be beneficial in patients with 
clinically isolated syndromes or relapsing-remitting 
multiple sclerosis.7,8 However, the production of 
neutralising antibodies against interferon beta is a major 
obstacle in high-dose interferon beta therapy,9 despite an 
improvement in the formulation of subcutaneous 
interferon beta-1a.10 Methylprednisolone as an add-on 
therapy to interferon beta-1b has been shown to reduce 
the production of neutralising antibodies to interferon 
beta.11 Because methylprednisolone might enhance the 
therapeutic effect of interferon beta and reduce the 
concentrations of neutralising antibodies, we tested the 
efficacy and safety of oral methylprednisolone given every 
4 weeks as an add-on therapy to subcutaneous interferon 
beta-1a in patients with relapsing-remitting multiple 
sclerosis who had had at least one relapse during the previous 
12 months while taking interferon beta. 
Methods 
Patients 
The NORMIMS (NORdic trial of oral Methylprednisolone 
as add-on therapy to Interferon beta for the treatment 
of relapsing remitting Multiple Sclerosis) study was a 
multicentre, randomised, double-blind, parallel-group, 
from outpatient clinics at 29 neurology departments in 
Denmark, Norway, Sweden, and Finland. Recruitment 
started in August, 2003, and the last patient visit was on 
December 10, 2007. Eligible patients had multiple 
sclerosis according to the McDonald criteria12 and 
clinically defi nite relapsing-remitting multiple sclerosis 
as defi ned by the Poser criteria.13 Further inclusion 
criteria were: age 18–55 years; baseline expanded 
disability status scale (EDSS)14 score of 5·5 points or 
less; treatment with subcutaneous interferon beta-1a 
for at least the previous 12 months and at a dose of 
44 μg three times a week for at least the 3 months 
immediately before entering the study; and recent 
clinical activity, defi ned as at least one relapse during 
the previous 12 months, while on interferon beta. We 
also required patients to be prepared and able to follow 
the study protocol for the whole study period. Women 
of childbearing age had to use adequate methods of 
contraception during the study period and have a 
negative pregnancy test at screening. 
Patients were excluded if they had been treated 
previously with lymphoid irradiation, mitoxantrone, 
cyclophosphamide, or long-term systemic gluco- 
corticoids. Other excluded drugs and regimens were: 
azathioprine or other immunosuppressive drugs; 
ciclosporin, glatiramer acetate, or intravenous immuno- 
globulin within 6 months; change of interferon beta 
preparation or dose within 3 months; or treatment with 
corticosteroids or adrenocorticotropic hormone within 
8 weeks. Further exclusion criteria were: relapse within 
30 days of randomisation, epilepsy that was not 
controlled by antiepileptic drugs, and being a women of 
childbearing age who did not use appropriate birth 
control or was pregnant or breastfeeding. Also, we 
excluded patients if they had converted to secondary- 
progressive multiple sclerosis, had a history of peptic 
ulcer or current symptoms of dyspepsia, diabetes 
mellitus, alcohol or drug abuse, major depression, 
cardiac or renal insufficiency, or other serious medical 
disorders, or had any medical illness that needed 
treatment with systemic corticosteroids. Finally, we 
excluded patients who had had a previous severe 
reaction to corticosteroids, had increased circulating 
concentrations of the liver enzymes aspartate 
aminotransferase or alanine aminotransferase 
(>2·5 times the normal upper limit), leucopenia 
(<2500 leucocytes per μL), or thrombo cytopenia 
(<100 000 thrombocytes per μL). 
The NORMIMS study protocol was approved in 2002 
and 2003 by independent ethics committees and regulatory 
authorities in Denmark, Norway, Sweden, and Finland. 
The study was undertaken in accordance with the 
Declaration of Helsinki, the European Medicines Agency 
note for guidance on good clinical practice, and the laws 
and regulations for clinical research in the participating 
countries. All patients provided written informed consent 
before any study procedure was undertaken. 
Randomisation and masking 
We randomly assigned patients to treatment with either 
oral methylprednisolone or placebo. The randomisation 
list was generated by computer (SAS PROC PLAN 
version 8.1; SAS, NC, USA) in 16 blocks of 20, by an 
independent contract research organisation (Smerud 
Medical Research International AS, Oslo, Norway) by 
operators who were not otherwise involved with the 
implementation of the study. The randomisation number 
was sent to the investigator with an order form for the 
study drug. Methylprednisolone and placebo were 
supplied in packs of 60 tablets. Study medication was 
packed at the central pharmacy for Copenhagen County 
(Herlev, Denmark) by people who had no further role in 
the study. Thereafter, the study drug was sent to the 
investigator who was responsible for the conduct of the 
study at the study site and was usually one of treating 
physicians. The randomisation code was not known by 
Merck Serono, the investigator, or the patient. 
To maintain treatment blinding, we used the 
two-physician principle: a treating neurologist was 
responsible for overall care of the patient, including 
assessment and management of adverse events, and 
analysis of laboratory test results; and an evaluating 
neurologist assessed patients at scheduled visits and at 
unscheduled relapse examinations, but was not otherwise 
involved in patient care. Both the treating and evaluating 
physicians were unaware of treatment allocation. 
Procedures 
Oral methylprednisolone (100 mg) and placebo tablets 
were formulated to look, smell, and taste identical. Two 
tablets were taken after the morning meal for 5 days 
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consecutively every 4 weeks for at least 96 weeks, in 
combination with subcutaneous interferon beta-1a (44 μg 
three times a week). The drug accountability log was kept 
by the study nurse and monitored by a clinical research 
associate from the independent contract research 
organisation. 
At baseline, we collected demographic data, took a 
medical history, assessed inclusion and exclusion criteria, 
asked about concomitant treatments, and took readings of 
vital signs. We did a clinical neurological examination that 
included EDSS and multiple sclerosis functional composite 
(MSFC) scores;15 MSFC scores were calculated from the 
paced auditory serial addition test, the nine-hole peg test, 
and the timed 25-foot walk test. We also did an electro- 
cardiogram, a pregnancy test, laboratory tests (haematology, 
blood chemistry, thyroid-stimulating hormone, binding 
and neutralising antibodies, and standard urinalysis), 
measurements of bone density in the lumbar spine, and 
MRI. When all laboratory tests and MRI findings had been 
analysed, the patient was randomly allocated to a treatment 
arm, and the study medicine was dispensed. 
The treating physician examined the patient every 
12 weeks and recorded adverse events, concomitant 
medication, and the results of laboratory tests on their 
clinical record forms. The evaluating neurologist did 
neurological examinations, including EDSS score 
evaluation, at 24-week intervals and MSFC score 
evaluation at weeks 48 and 96. In the case of a suspected 
relapse, patients were examined within 7 days from onset 
of symptoms. The study was terminated when the last 
enrolled patient had completed 96 weeks of follow-up. 
We measured neutralising antibody concentrations at 
baseline and weeks 24, 48, 72, and 96 with an antiviral 
neutralisation bioassay (Biomonitor, Copenhagen, 
Denmark).16 We defined a sample as positive for 
neutralising antibodies if it had a neutralising capacity 
of at least 20%, because this value was previously shown 
as the lowest concentration of neutralising antibodies to 
have clinical importance.17 We used the “anytime positive, 
always positive” (ie, based on one positive sample) 
principle to classify patients as positive for neutralising 
antibodies.18 
We did brain MRI scans at baseline and week 96 
according to a standard procedure and used the same 
MRI scanners at each visit, operating at 1·0 or 1·5 T. 
Gadolinium contrast was not used. For lesion assessment, 
we obtained 3 mm axial images (fi eld of view 250 mm; 
matrix 256×256) with a proton-density and T2-weighted 
turbo-spin-echo sequence (50 slices) and a fl uid-attenuated 
inversion recovery (FLAIR) sequence (36–50 slices). To 
analyse brain atrophy, we acquired a three-dimensional 
T1-weighted gradient-echo sequence (128–170 slices of 
1·0–1·3 mm; field of view 250 mm; matrix 256×256). All 
two-dimensional images from both sessions were 
coregistered and resliced to the T2-weighted image of a 
random session (baseline or follow-up) so as not to 
introduce systematic differences due to the reslicing, with 
the Statistical Parametric Mapping 2 (SPM2) toolbox. 
A trained technician manually delineated the lesions 
seen on the FLAIR images with in-house developed 
software, and these lesions were checked and corrected 
by a physician with experience of this procedure; the 
technician and physician were blinded to treatment 
allocation and the order of the images. We used the 
delineated lesions to calculate lesion volumes and the 
number of new or enlarging lesions. On follow-up 
images, we defi ned a lesion as new if it did not overlap 
with a lesion seen on the baseline images by more than 
20% for small lesions (volume less than that of a sphere 
of 5 mm diameter) or 50% for larger lesions (volume 
greater than that of a sphere of 5 mm diameter). We 
judged a lesion to be enlarged if its volume had 
increased by 50% for small lesions or by 20% for large 
lesions compared with overlapping lesions on baseline 
images. 
We estimated brain parenchymal volumes and brain 
parenchymal fractions on magnetisation-prepared rapid 
gradient-echo (MPRAGE) images with the Oxford Centre 
for Functional MRI of the Brain (FMRIB) Automated 
Segmentation Tool (FAST),19 which is part of the FMRIB 
software library (FSL) software library version 3.3.11.20 
We used structural image evaluation, using 
normalisation, of atrophy (SIENA version 2.4; Oxford, 
UK),21 which is also part of FSL, to estimate the percentage 
change in brain volume between baseline and week 96. 
For patients who withdrew from the study prematurely, 
we did a brain MRI at 8 weeks after the last dose of study 
drug. 
The primary outcome measure was mean number of 
documented relapses per patient per year (mean yearly 
relapse rate) during weeks 0–96. This endpoint was 
recorded in the original protocol, but was changed in a 
later version of the protocol to “mean number of 
documented relapses per patient per year at 48 and 
96 weeks”. However, to avoid having more than one 
primary endpoint, the original primary outcome measure 
was re-established before the end of the study when all 
data in the database were still masked. Relapses were 
defi ned, according to Schumacher and colleagues,22 as 
the appearance of new, or worsening of old, neurological 
symptoms, without fever, that persisted for more than 
48 h, and were preceded by more than 30 days with a 
stable or improving condition. A documented (qualifying) 
relapse was defi ned as a relapse that caused objective 
changes seen on neurological examination, whereas 
changes in bowel and bladder function could not solely 
be classifi ed as documented relapses. An undocumented 
(non-qualifying) relapse was defi ned as a relapse that 
fulfi lled the defi nition of Schumacher and colleagues 
without new changes in the neurological examination. 
Secondary endpoints were mean yearly relapse rate 
during weeks 0–48 and weeks 49–96; time to worsening 
of disability assessed as an increase of 1 point or more in 
EDSS score and confi rmed at two consecutive visits 
24 weeks apart; changes in MSFC score from baseline to 
week 48 and from baseline to week 96; number of active 
lesions (new or enlarging lesions) on T2-weighted MRI; 
and the presence of neutralising antibodies at any point 
up to week 96. 
The tertiary endpoints were: total number of reported 
relapses; probability of remaining relapse free and other 
relapse-related outcomes; proportion of patients with 
disability progression, total volume of lesions on 
T2-weighted MRI; and change in normalised brain 
parenchymal volume. 
For safety comparisons, we recorded adverse events, 
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withdrawals due to adverse events, serious adverse events, 
bone-density measurements, and laboratory test results. 
Statistical analysis 
On the basis of data from the Prevention of Relapses and 
Disability by Interferon beta-1a Subcutaneously in 
Multiple Sclerosis (PRISMS) study,2 the yearly relapse 
rate in the interferon beta-1a plus placebo group was 
estimated as 0·8 and the relative reduction in relapses as 
30% in the interferon beta-1a plus methylprednisolone 
group. We calculated that a sample size of 130 patients in 
each group would be needed to reach a power of 80%. We 
anticipated a dropout rate of 15%; hence, a cohort of 
300 patients was planned for the trial. However, enrolment 
was discontinued prematurely after 130 patients had been 
randomised, owing to slow recruitment. 
All statistical analyses were approved by the NORMIMS 
study steering committee before unmasking. The 
primary analyses were intention to treat, which included 
all randomised patients, whereas patients who completed 
96 weeks of treatment and assessments without any 
major protocol deviations were included in the 
per-protocol analyses. 
We assessed baseline comparability 
with a two-way analysis-of-variance model and categorical 
variables with χ² tests. We analysed the primary endpoint 
(mean yearly relapse rate) with a Poisson regression 
model; to estimate the eff ect of baseline variables on the 
primary outcome we used multiple Poisson regression 
analysis. If the EDSS score was missing for a visit, we 
deemed disability as not increased for that visit compared 
with the previous visit. The probability of remaining 
relapse free and the increase in disability measured with 
the EDSS were estimated by Kaplan–Meier survival 
analysis, and we assessed the differences in the survival 
curves with the log-rank test. We analysed the MSFC 
with the t distribution at every visit to the evaluating 
neurologist. MSFC scores were standardised to the mean 
baseline MSFC value for the intention-to-treat 
population.23 We used Poisson regression to evaluate the 
number of active lesions on MRI. The occurrence of 
neutralising antibodies was analysed with logistic 
regression and proportional odds models, both with and 
without adjustment for baseline status. For sensitivity 
analyses of the primary outcome measure, we used the 
Poisson regression model for multiple imputations of 
relapses for early dropouts. We used 200 imputations for 
every missing observation and combined the results in 
accordance with standard methods.24 All statistical tests 
were two-sided (α=0·05). All models were checked for 
assumption violations. Poisson models were tested for 
overdispersion and underdispersion and, if necessary, 
adjusted with quasi-likelihood estimates.25 We did all 
calculations with SAS version 9.1.3 (SAS Institute, Cary, 
NC, USA). 
This trial is registered, number ISRCTN16202527. 
Role of the funding source 
Data management and analyses were done by an 
independent contract research organisation (Smerud 
Medical Research International AS, Oslo, Norway). The 
sponsor of the study had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results 
130 patients were randomly assigned to add-on therapy: 
66 to oral methylprednisolone and 64 to placebo (figure 1). 
Table 1 shows baseline demographics and clinical 
characteristics. 
The number of scheduled visits was similar between 
treatment groups (380 in the methylprednisolone group 
vs 382 in the placebo group), whereas more unscheduled 
visits were made for suspected relapses by patients in 
the placebo group (n=79) than by patients in the 
methylprednisolone group (n=51). 75 patients completed 
follow-up and 55 patients discontinued study medication 
prematurely, but 27 of the patients who withdrew did so 
after week 96; therefore, 102 patients completed 
96 weeks or longer of follow-up (fi gure 1). The longest 
follow-up was 126 weeks. 
Adherence, as measured according to the entries in the 
drug accountability log, was similar between groups (mean 
88% [SD 39] in the methylprednisolone group and 86% 
[28] in the placebo group). 
Table 2 shows the distribution of documented relapses 
in the two treatment groups up to week 96. In the 
intention-to-treat population, there were 23 relapses in 
the methylprednisolone group and 66 relapses in the 
placebo group. Total treatment duration was 103·6 years 
for patients randomly assigned to methylprednisolone 
and 112·0 years for those assigned to placebo, giving a 
mean yearly relapse rate of 0·22 (95% CI 0·15–0·33) on 
methylprednisolone and 0·59 (0·46–0·75) with placebo 
(relative reduction in relapse rate 62%, 95% CI 39–77%; 
p<0·0001). Only minor diff erences in mean yearly relapse 
rate were recorded between treatment groups during 
weeks 0–48 (relative reduction 63%, 32–80%; p=0·002) 
and during weeks 48–96 (relative reduction 62%, 19–82%; 
p=0·013). In the per-protocol population, four relapses 
occurred during 49·8 patient-years in the 
methylprednisolone group and 29 relapses during 
69·3 patient-years in the placebo group (yearly relapse 
rate 0·08 vs 0·42; relative reduction in relapse rate 81%, 
45–93%; p=0·002). 
Because many patients withdrew from the study, we 
did sensitivity analyses to assess the effect of early 
withdrawals on the measurement of relapse activity. We 
imputed recorded relapses for the remainder of the study 
(from withdrawal to 96 weeks) and calculated the 
estimated relapse ratio. Assuming a yearly relapse rate of 
0·59 (which is the mean yearly relapse rate for the 
placebo group) for all patients who withdrew, the 
diff erence between treatment groups was signifi cant 
(estimated relapse rate ratio 0·49, 95% CI 0·31–0·76; 
p=0·002). If we assume a yearly relapse rate of 1·2 (twice 
the mean yearly relapse rate for the placebo group), the 
estimated relapse rate ratio was 0·61 (0·40–0·91; 
p=0·017). Finally, assuming a yearly relapse rate of 1·2 
for patients who withdrew because of adverse events and 
0·6 for patients who withdrew for other reasons, the 
estimated relapse ratio was 0·58 (0·37–0·90; p=0·015). 
35 reported relapses (documented and undocumented) 
in 103·6 patient-years occurred in the methyl prednisolone 
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group and 92 relapses occurred in 112·0 patient-years in 
the placebo group (yearly relapse rate 0·34 vs 0·82; 
between-group diff erence 0·41, 95% CI 0·28–0·61; 
p<0·0001) in the intention-to-treat population. 21 relapses 
in the methylprednisolone group and 70 relapses in the 
placebo group were treated with glucocorticoids. Mean 
time to fi rst recorded relapse was 30·8 (SD 23·5) weeks in 
the methylprednisolone group compared with 34·9 (26·2) 
weeks in the placebo group. By Kaplan–Meier estimate, 
the probability of remaining relapse free throughout the 
trial was 76% in the methylprednisolone group compared 
with 34% in the placebo group (between-group absolute 
diff erence 42% [95% CI 26–58%]; log-rank p<0·0001). We 
also did a sensitivity analysis of the relapse-free patients 
that assumed the best scenario (no relapses in the 
dropouts) and the worst scenario (all dropouts had a 
relapse). For the best scenario, the estimated odds ratio 
would be 0·15 (95% CI 0·06–0·36; p<0·0001); for the 
worst scenario, the estimated odds ratio would be 0·48 
(0·22–1·05; p=0·064). 
To account for any interaction between baseline 
variables and treatment outcome, the yearly relapse rate 
was analysed according to EDSS score (0–2·5 points 
[eg, no or negligible disability] vs 3·0–5·5 points [eg, 
some disability]), number of relapses in the 12 months 
before randomisation (one vs two or more), ascertained 
from documentation or patient recollection, age (older or 
younger than the median age of 38·7 years for the 
intention-to-treat population), sex, and country. A 
significant interaction was noted between treatment 
effect and baseline EDSS score (p=0·007), implying that 
no treatment effect was seen for patients with a baseline 
EDSS of 3 points or more. However, the overall treatment 
effect adjusted for baseline EDSS was signifi cant (relapse 
rate ratio 0·33, 95% CI 0·19–0·56; p<0·0001). This 
interaction effect could be accounted for by diff erences in 
withdrawals: more patients with low baseline EDSS 
scores withdrew in the methylprednisolone group (n=20) 
compared with patients in the placebo group (n=7). No 
other signifi cant interactions were reported. 
Figure 2 shows the Kaplan–Meier estimates of an 
increase in disability by 1 point or more on the EDSS, 
confi rmed at 24 weeks. The difference between groups 
was not statistically signifi cant (p=0·29), with an 
estimated probability of progression at 96 weeks of 16% 
(95% CI 6–26%) in the methylprednisolone group and 
25% (13–36%) in the placebo group (36% reduction [95% 
CI –37 to 70%]). 
Table 3 shows the MSFC score and its subscales and 
change from baseline to weeks 48 and 96. MSFC score 
was calculated from the results of the paced auditory serial 
addition test, the nine-hole peg test, and the timed 25-foot 
walk test. Scores were standardised to the baseline MSFC 
score for the intention-to-treat population.23 The difference 
between treatments in MSFC score from baseline to week 
48 was –0·11 (95% CI –0·26 to 0·05; p=0·17), and –0·05 
(–0·22 to 0·11; p=0·52) from baseline to week 96. 
MRI at baseline and at study termination (after 
96 weeks or after discontinuation of study drug) was 
done in 54 patients in the methylprednisolone group and 
56 patients in the placebo group. 34 of 55 patients who 
withdrew underwent MRI after discontinuation of the 
study drug. In the methylprednisolone group, 253 active 
lesions were recorded in 92·8 patient-years, whereas 
369 active lesions in 104·4 patient-years were noted in 
the placebo group. 
The mean number of new or enlarging lesions per 
patient per year was 2·7 (95% CI 2·0–3·8) in the methyl- 
prednisolone group and 3·5 (2·7–4·7) in the placebo 
group (23% reduction; relative rate ratio 0·77, 95% CI 
0·50–1·19; p=0·24). Table 4 shows the changes in 
T2-lesion volume and normalised brain parenchymal 
volume from baseline. 
Neutralising antibodies were detected at least once in 
12 of 47 (26%) patients in the methylprednisolone group 
and in 16 of 46 (35%) patients in the placebo group. Some 
blood samples contained toxic substances (eg, bacterial 
endotoxins) or endogenous antiviral activity that 
prevented measurement of neutralising antibodies. 
Nine (23%) of 39 patients in the methylprednisolone 
group and 13 (30%) of 43 patients in the placebo group 
were positive for neutralising antibodies at 96 weeks. 
Table 5 shows the yearly relapse rate and number of new 
or enlarging T2 lesions seen on MRI in patients grouped 
according to neutralising antibody status. 
Because an unexpectedly high number of patients 
discontinued study medication, additional analyses were 
done to assess whether withdrawal of the study drug in 
these patients had aff ected the assessment of treatment 
efficacy. Of 18 patients who discontinued methyl- 
prednisolone but completed follow-up at 96 weeks, 
15 continued with interferon beta-1a as the only 
immunomodulatory drug, two were treated with 
mitoxantrone, and one received glatiramer acetate. Of 
the nine patients in the placebo group who discontinued 
placebo but completed follow-up at 96 weeks, five 
continued with interferon beta-1a as the only immuno- 
modulatory drug, two were treated with mitoxantrone, 
and two received natalizumab. Mean time in the trial 
after treatment termination was 53·4 weeks (SD 37·3) in 
the methylprednisolone group and 29·4 weeks (25·7) in 
the placebo group. Post-hoc analysis showed no difference 
between the treatment groups for mean time to sustained 
increase in disability or number of patients with a 
sustained increase in disability in the patients who 
discontinued. 
Table 6 shows adverse events according to treatment 
group. More adverse events were recorded in the 
methylprednisolone group than in the placebo group: 
18 patients (27%) assigned to methylprednisolone and two 
(3%) assigned to placebo withdrew from the study because 
of adverse events. Most adverse events in both groups were 
deemed by the investigators as possibly or probably related 
to the treatment. In particular, psychiatric symptoms, 
mainly insomnia and restlessness, and gastrointestinal 
symptoms, particularly dyspepsia, were reported more 
frequently by the methylprednisolone group than they 
were by the placebo group. Neurological symptoms were 
also reported more frequently by the methylprednisolone 
group than by the placebo group; changes in taste 
(dysgeusia and ageusia) were the most common. Osteo- 
porosis was recorded as an adverse event in three patients 
in each group. Measurements of bone mineral density of 
the lumbar spine showed small changes from baseline at 
week 96: a mean reduction of 2·8% (SD 6·3%) in the 
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methylprednisolone group, whereas in the placebo group 
the decline was 0·6% (5·9%). More abnormalities in the 
results of laboratory tests were recorded in the methyl- 
prednisolone group than in the placebo group, but few of 
the abnormalities were judged as clinically significant by 
the investigators: in the methylprednisolone group, fi ve 
patients had increased liver enzymes, one had leucopenia, 
and one had an increased white blood cell count. 
Serious adverse events were reported by ten patients 
(11 events). In the methylprednisolone group, one person 
was admitted to hospital owing to urosepsis and another 
was admitted because of a peritoneal infection; both 
events were deemed treatment related. One patient was 
admitted to hospital for arthroscopy of the knee, which 
was unrelated to the study drug; one had severely raised 
concentrations of liver enzymes ascribed to the interferon 
beta treatment; and another had recurrence of a cancer 
in the parotid gland, which was unrelated to the study 
drug. In the placebo group, one patient had two serious 
adverse events—a deep vein thrombosis in the right 
lower limb and an extrauterine pregnancy; both adverse 
events were deemed unrelated to the study drug. Another 
patient was admitted to hospital with dystonia that started 
before the fi rst dose of study drug and was therefore 
regarded as unrelated to treatment. One patient was 
admitted to hospital for a cholecystectomy, another was 
admitted with pyelonephritis, and another with severe 
migraines, which were deemed as unrelated to the 
treatment drug by the investigator. One patient in the 
placebo group died during the trial after admission to 
hospital with signs of pneumonia; this was not deemed 
related to the treatment by the investigator and a 
post-mortem examination was not done. 
Discussion 
The findings of the NORMIMS study showed that add-on 
therapy of oral methylprednisolone for 96 weeks 
in patients with relapsing-remitting multiple sclerosis 
reduced the yearly relapse rate compared with that 
of patients on placebo. Unfortunately, the enrolment 
of patients had to be terminated prematurely because of 
slow recruitment; therefore, we believe the study was 
underpowered to show the predicted 30% reduction in 
relapse rate. However, our fi ndings showed that 
methylprednisolone as an add-on therapy had a positive 
effect on the primary outcome measure was owing to a 
higher than expected reduction in relapse rate. 
There was no difference in the main secondary MRI 
outcome—new or enlarging T2 lesions—in the 
methylprednisolone group compared with the placebo 
group. The difference between the effect on relapse-related 
outcomes and on new or enlarging T2 lesions is 
intriguing, and we cannot provide a clear explanation. 
However, the converging evidence of a treatment effect 
of methylprednisolone was encouraging, and all 
secondary and tertiary efficacy measures were in favour 
of methylprednisolone, although the change in 
T2-weighted lesion volume was the only MRI measure 
that reached statistical signifi cance. 
Differences in baseline characteristics were minor, and 
multiple regression analysis that included the baseline 
variables showed only an interaction between EDSS and 
treatment response, which could not explain the 
difference in treatment effect between methylpred- 
nisolone and placebo. 
As is reported in other studies of effective drugs for 
multiple sclerosis, more unscheduled visits for suspected 
relapses were reported in the placebo group than in the 
methylprednisolone group. Although this difference was 
expected, we cannot exclude the possibility that the 
higher number of unscheduled visits from patients 
taking placebo might have introduced a slight bias, 
because unscheduled visits could increase the chance of 
documenting a relapse. 
Our study was hampered by an unexpectedly high 
number of patients who discontinued their assigned 
medication or withdrew. We did analyses to see if treatment 
with another drug after discontinuation of the assigned 
regimen in patients who continued follow-up could have 
introduced bias that might have affected the results. 
Patients who discontinued their assigned study drug 
received mitoxantrone, glatiramer acetate, or natalizumab, 
or some continued treatment with interferon beta only. 
Mitoxantrone4 and natalizumab6 are thought of as more 
effective second-line therapies than is interferon beta;2 
however, most patients who stopped methylprednisolone 
treatment continued on interferon beta-1a only. Hence, we 
do not think that any diff erences in disease-modifying 
therapy after discontinuation of study drug could have 
contributed to the recorded diff erence in therapeutic eff ect 
between the two treatment groups. 
The most frequent reasons for premature withdrawal 
from the study were adverse events in the 
methylprednisolone group and lack of efficacy in the 
placebo group. Because the patients who withdrew did not 
continue follow-up, we cannot control for any bias. 
However, the findings of the sensitivity analyses showed 
that rejection of the primary null hypothesis is robust to 
deviations from the assumption that data are missing at 
random (MAR) in the primary analysis.24 
Baseline characteristics, discontinuation of study drug, 
or study withdrawal did not seem to account for the 
recorded difference in treatment effect between 
methylprednisolone and placebo. However, we cannot 
exclude the possibility that unknown factors with regard 
to the patients who either discontinued the study drugs or 
left the study could have affected our results. 
We chose a monthly regimen of methylprednisolone in 
our study because the genomic and non-genomic effects 
of a 5-day administration of a glucocorticoid in a month 
are short lived,26 and the effect on gadolinium-enhancing 
lesions is signifi cant at 1 month, but not at 2 months, 
after high-dose intravenous methylprednisolone.27,28 The 
monthly dose of methylprednisolone was similar to that 
used in a randomised placebo-controlled trial of pulsed 
methylprednisolone therapy.8 Oral methylprednisolone 
is equivalent to the same dose given intravenously,29 and 
one 200 mg dose fully saturates the glucocorticoid 
cytosolic receptors.30 
Glucocorticoids have many effects on the immune 
system.31 Their effects on the blood–brain barrier can be 
seen as attenuation of gadolinium enhancement and 
correlate with macrophage infi ltration into the multiple 
sclerosis lesions in the brain.32,33 Glucocorticoids interact 
negatively with transcription factors that have a role in 
T-cell activation and can induce apoptosis of activated 
T cells34,35 and diminish the expression of CD26 on 
CD4+ T cells.36 High doses of methylprednisolone induce 
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expression of transforming growth factor beta, which 
inhibits production of proinfl ammatory cytokines by 
effector T cells.37,38 Also, the decline in IgG synthesis seen 
after treatment with high doses of oral methylprednisolone 
could be implicated in the clinical response.39 
An additive or synergistic effect of glucocorticoids and 
interferon beta could be mediated by the ability of 
glucocorticoids to increase the sensitivity of T cells to 
interferon beta and upregulate interferon receptors. 
These effects have anti-infl ammatory potential, mediated 
by increased production of interleukin 10 and suppressed 
secretion of interferon gamma by T cells.40 
The results of the NORMIMS study are in agreement 
with those of previous trials that show a detrimental 
effect of neutralising antibodies on the therapeutic 
efficacy of interferon beta,17 despite a study duration of 
nearly 2 years and our use of the “anytime positive, 
always positive” method, which underestimates the 
effects of neutralising antibodies.18 Furthermore, our 
fi ndings confi rmed previous work that showed that 
methylprednisolone does not reduce the concentrations 
of already induced neutralising antibodies.41 
A randomised, single-blind, phase II trial compared 
intravenous cyclic methylprednisolone (1 g daily for 
5 days and a prednisolone taper, administered every 
4 months for 3 years and then every 6 months for 2 years) 
with no other treatment apart from management of acute 
relapses with methylprednisolone.8 Patients who received 
cyclic methylprednisolone showed a 32% reduction in 
the probability of a sustained increase in EDSS score. 
Changes in the volume of T1 black holes and in brain 
parenchymal volume also favoured pulsed treatment 
with methylprednisolone.8 No differences were recorded 
between the two groups in yearly relapse rate (0·6 in both 
groups), but less frequent administration of methyl- 
prednisolone than in NORMIMS might have contributed 
to the absence of an effect of methylprednisolone on 
relapses. 
In the Optic Neuritis Study,7 one course of intravenous 
methylprednisolone (1 g daily for 3 days with an oral 
taper) compared with placebo reduced the risk for 
developing defi nite multiple sclerosis at 2 years (odds 
ratio 0·43). However, at 5 years the effect had disappeared, 
which could be why this finding of the Optic Neuritis 
Study has been widely ignored. In fact, in the Controlled 
High-risk Avonex Multiple Sclerosis study (CHAMPS),42 
37% of patients in the optic neuritis cohort developed 
defi nite multiple sclerosis within 2 years on interferon 
beta-1a therapy, and the 95% CI included the optic 
neuritis study estimate of 28%.43 However, these study 
populations might not have been comparable, because 
cerebral MRI changes were required for inclusion in the 
CHAMPS study, whereas 52% of patients in the optic 
neuritis study had no brain lesions on MRI, and 
these patients had a particularly low risk for developing 
clinically defi nite multiple sclerosis. 
A regimen of high-dose intravenous methylpredni- 
solone (500 mg daily for 3 consecutive days with an oral 
taper) was compared with a low-dose regimen (10 mg 
daily for 3 consecutive days with an oral taper given every 
other month for up to 2 years) in 108 patients with 
secondary-progressive multiple sclerosis.44 No difference 
was recorded between the two doses with respect to the 
primary outcome measure—proportion of patients with 
sustained progression (low dose 54% vs high dose 39%; 
p=0·18). However, a Kaplan–Meier analysis of time to 
sustained progression was in favour of high-dose 
methylprednisolone (p=0·04). 
The SENTINEL (safety and efficacy of natalizumab in 
combination with interferon beta-1a in patients with 
relapsing-remitting multiple sclerosis) study was a large, 
randomised, double-blind, placebo-controlled study of 
natalizumab as an add-on therapy to intramuscular 
interferon beta-1a versus placebo in patients who had 
breakthrough disease on interferon beta therapy.45 The 
characteristics of the patients in the SENTINEL study 
were similar to those of our population with regard to 
age, EDSS score, relapse activity, and duration of 
interferon beta therapy, whereas the proportion of men 
was lower and the mean time since onset slightly longer 
(table 7). In the natalizumab arm, the relapse rate 
reduction was 54% and the decline in the probability of 
sustained EDSS progression was 24% compared with 
placebo. These efficacy measures are not very different 
from those reported in our study. 
In the Avonex Combination Therapy (ACT) study,46,47 
bimonthly intravenous methylprednisolone (1000 mg 
daily for 3 consecutive days; n=66) was compared with 
methotrexate (20 mg daily; n=76), the combination of the 
two drugs (n=74), and placebo (n=70) as an add-on 
therapy to intramuscular interferon beta-1a (30 μg per 
week for 12 months) in patients with relapsing-remitting 
multiple sclerosis who had had a relapse during the 
previous year while on intramuscular interferon beta-1a 
or who had gadolinium-enhancing lesions seen on 
baseline MRI of the brain. Similar to the NORMIMS 
study, the ACT trial was stopped early because of slow 
recruitment: the original plan was to enrol 900 patients, 
with follow-up of 24 months, and relapse rate as the 
primary outcome;46 however, the trial was discontinued 
after 313 patients were enrolled, the study time was 
reduced to 12 months, and the primary endpoint was 
changed to the number of new or enlarging T2 lesions 
on brain MRI. In the 12-month study, 23 out of 78 patients 
(29%) in the placebo group and 23 out of 74 patients 
(31%) in the methylprednisolone group discontinued the 
study or study medication. The ACT study used a 2×2 
factorial design, which makes direct comparison of the 
treatment effect of methylprednisolone versus placebo 
with the effect in our study difficult. Several of the ACT 
outcome measures favoured methylprednisolone, as 
they seem to do in our study, although the diff erences 
were not signifi cant: relapse rate ratio 0·70, 95% CI 
0·42–1·17 (p=0·17); odds ratio of change in EDSS score 
0·76, 0·47–1·22 (p=0·25); ratio of probability of 
progression 0·62, 0·26–1·48 (p=0·24); and odds ratio of 
new or enlarging T2 lesions 0·74, 0·47–1·15 (p=0·18). 
Furthermore, the ACT study was underpowered to show 
effects on clinical endpoints, with relative reductions of 
about 30%. Compared with our study, the most notable 
differences in the ACT trial were shorter study duration, 
reduced frequency of methylprednisolone administration, 
and no blinding of the intravenous methylprednisolone 
treatment.46,47 To ascertain whether the frequency of 
methylprednisolone administration aff ects relapse rate 
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will require a large dose-comparison study. By 
comparison with our study population, patients in the 
ACT trial were older, had longer duration of disease, and 
had lower relapse activity in the 12 months before 
inclusion (table 7). 
The methylprednisolone in combination with 
interferon beta-1a (MECOMBIN) study is a multicentre, 
double-blind, randomised, parallel-group trial of 
341 patients with relapsing-remitting multiple sclerosis 
who are treatment naive; the fi ndings of this trial are as 
yet unpublished but have been presented as an abstract 
at the 2009 American Academy of Neurology annual 
meeting.48 Patients were randomly assigned to either 
methylprednisolone (500 mg per day for 3 consecutive 
days every month for 3–4 years; n=172) or placebo (n=169) 
as add-on treatment to intramuscular interferon beta-1a. 
The yearly recorded relapse rate was 0·205 in the 
methylprednisolone group and 0·333 in the placebo 
group (relative reduction 38%; p<0·01). Time to sustained 
progression did not diff er between treatment groups 
(hazard ratio 0·8; p=0·33). Mean MSFC score rose by 
0·06 in the methylprednisolone group, but decreased by 
0·14 in the placebo group (p<0·05). Median change in 
T2-lesion volume was –69 mm³ in the methylprednisolone 
group and 71 mm³ in the placebo group (p<0·02). 
In conclusion, the addition of monthly oral 
methylprednisolone pulses to subcutaneous interferon 
beta-1a treatment was safe, and although many patients 
in the treatment arm dropped out, most patients tolerated 
methylprednisolone as an add-on to interferon beta-1a. 
The addition of methylprednisolone signifi cantly reduced 
the relapse rate and might also benefi t disease progression 
and disease activity seen on MRI. Our fi ndings are 
important because oral methylprednisolone is 
inexpensive and easily administered in patients with 
breakthrough disease who are on interferon beta therapy. 
Owing to the limited number of patients and the high 
proportion of patients who discontinued therapy in the 
NORMIMS trial, the fi ndings should be corroborated in 
larger trials. Furthermore, the results of the large 
MECOMBIN study need to be scrutinised before any 
final conclusions can be made with regard to the effect of 
methylprednisolone as an add-on therapy to interferon 
beta. On the basis of the results of the NORMIMS study, 
cyclic oral methylprednisolone as an add-on therapy to 
interferon beta could be an important alternative to more 
expensive and potentially more harmful therapies 
for patients with relapsing-remitting multiple sclerosis 
whose disease is insufficiently controlled by first-line 
therapies. 
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anticipated a dropout rate of 15%; hence, a cohort of 
300 patients was planned for the trial. However, enrolment 
was discontinued prematurely after 130 patients had been 
randomised, owing to slow recruitment.
All statistical analyses were approved by the NORMIMS 
study steering committee before unmasking. The 
primary analyses were intention to treat, which included 
all randomised patients, whereas patients who completed 
96 weeks of treatment and assessments without any 
major protocol deviations were included in the 
per-protocol analyses. We assessed baseline comparability 
with a two-way analysis-of-variance model and categorical 
variables with χ² tests. We analysed the primary endpoint 
(mean yearly relapse rate) with a Poisson regression 
model; to estimate the eff ect of baseline variables on the 
primary outcome we used multiple Poisson regression 
analysis. If the EDSS score was missing for a visit, we 
deemed disability as not increased for that visit compared 
with the previous visit. The probability of remaining 
relapse free and the increase in disability measured with 
the EDSS were estimated by Kaplan–Meier survival 
analysis, and we assessed the diff erences in the survival 
curves with the log-rank test. We analysed the MSFC 
with the t distribution at every visit to the evaluating 
neurologist. MSFC scores were standardised to the mean 
baseline MSFC value for the intention-to-treat 
population.23 We used Poisson regression to evaluate the 
number of active lesions on MRI. The occurrence of 
neutralising antibodies was analysed with logistic 
regression and proportional odds models, both with and 
without adjustment for baseline status. For sensitivity 
analyses of the primary outcome measure, we used the 
Poisson regression model for multiple imputations of 
relapses for early dropouts. We used 200 imputations for 
every missing observation and combined the results in 
accordance with standard methods.24 All statistical tests 
were two-sided (α=0·05). All models were checked for 
assumption violations. Poisson models were tested for 
overdispersion and underdispersion and, if necessary, 
adjusted with quasi-likelihood estimates.25 We did all 
calculations with SAS version 9.1.3 (SAS Institute, Cary, 
NC, USA).
This trial is registered, number ISRCTN16202527. 
Role of the funding source 
Data management and analyses were done by an 
independent contract research organisation (Smerud 
Medical Research International AS, Oslo, Norway). The 
sponsor of the study had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
130 patients were randomly assigned to add-on therapy: 
66 to oral methylprednisolone and 64 to placebo (fi gure 1). 
Table 1 shows baseline demographics and clinical 
characteristics. 
The number of scheduled visits was similar between 
treatment groups (380 in the methylprednisolone group 
vs 382 in the placebo group), whereas more unscheduled 
visits were made for suspected relapses by patients in 
the placebo group (n=79) than by patients in the 
methylprednisolone group (n=51). 75 patients completed 
follow-up and 55 patients discontinued study medication 
prematurely, but 27 of the patients who withdrew did so 
after week 96; therefore, 102 patients completed 
 Methylprednisolone 
(n=66)
Placebo (n=64)
Age (years) 37·8 (7·4) [39·2] 39·5 (7·8) [38·5] 
Men 29 (44%) 21 (33%)
Time since onset of symptoms (years) 6·9 (5·1) [5·3] 8·5 (5·9) [7·0] 
EDSS score 2·5 (1·3) [2·5] 2·9 (1·4) [3·0] 
Number of relapses within previous year 1·6 (0·9) [1·0] 1·5 (1·0) [1·0] 
Relapses in previous year
1 41 (62%) 45 (70%)
2 15 (23%) 13 (20%)
≥3 10 (15%) 6 (9%)
Duration of interferon beta-1a treatment (years) 2·8 (1·8) [2·3] 3·4 (2·1) [2·8]
T2 lesion volume (mm³) 7671·9 (8705·3) [3888·0]* 11 507·7 (14 538·0) [6054·0]† 
Brain parenchymal volume (cm³) 1184·1 (127·5) [1189·0]‡ 1166·1 (142·4) [1140·5]§ 
Number positive for neutralising antibodies 12/47 (26%) 16/46 (35%)
Data are mean (SD), [median], or number of patients (%). EDSS=expanded disability status scale. *n=56. †n=54. 
‡=55. §n=52. 
Table 1: Baseline demographics and clinical characteristics 
66 randomly assigned to interferon
beta-1a and methylprednisolone
(ITT population)
17 withdrew before 96 weeks
7 had adverse events
3 due to no efficacy
6 for personal reasons
1 for other reason
18 discontinued therapy but 
completed 96 weeks of 
follow-up
11 had adverse events
1 due to no efficacy
4 for personal reasons
2 for other reasons
49 completed at least 96 weeks of
follow-up
53 completed at least 96 weeks of
follow-up
9 discontinued therapy but 
completed 96 weeks of 
follow-up
5 due to no efficacy
1 for personal reasons
3 for other reasons
11 withdrew before 96 weeks
2 had adverse events
4 due to no efficacy
1 for personal reasons
1 died
3 for other reasons
64 randomly assigned to interferon
beta-1a and placebo
(ITT population)
130 patients enrolled
Figure 1: Trial profi le  
ITT=intention to treat.
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96 weeks or longer of follow-up (fi gure 1). The longest 
follow-up was 126 weeks. 
Adherence, as measured according to the entries in the 
drug accountability log, was similar between groups (mean 
88% [SD 39] in the methylprednisolone group and 86% 
[28] in the placebo group). 
Table 2 shows the distribution of documented relapses 
in the two treatment groups up to week 96. In the 
intention-to-treat population, there were 23 relapses in 
the methylprednisolone group and 66 relapses in the 
placebo group. Total treatment duration was 103·6 years 
for patients randomly assigned to methylprednisolone 
and 112·0 years for those assigned to placebo, giving a 
mean yearly relapse rate of 0·22 (95% CI 0·15–0·33) on 
methylprednisolone and 0·59 (0·46–0·75) with placebo 
(relative reduction in relapse rate 62%, 95% CI 39–77%; 
p<0·0001). Only minor diff erences in mean yearly relapse 
rate were recorded between treatment groups during 
weeks 0–48 (relative reduction 63%, 32–80%; p=0·002) 
and during weeks 48–96 (relative reduction 62%, 19–82%; 
p=0·013). In the per-protocol population, four relapses 
occurred during 49·8 patient-years in the 
methylprednisolone group and 29 relapses during 
69·3 patient-years in the placebo group (yearly relapse 
rate 0·08 vs 0·42; relative reduction in relapse rate 81%, 
45–93%; p=0·002).
Because many patients withdrew from the study, we 
did sensitivity analyses to assess the eff ect of early 
withdrawals on the measurement of relapse activity. We 
imputed recorded relapses for the remainder of the study 
(from withdrawal to 96 weeks) and calculated the 
estimated relapse ratio. Assuming a yearly relapse rate of 
0·59 (which is the mean yearly relapse rate for the 
placebo group) for all patients who withdrew, the 
diff erence between treatment groups was signifi cant 
(estimated relapse rate ratio 0·49, 95% CI 0·31–0·76; 
p=0·002). If we assume a yearly relapse rate of 1·2 (twice 
the mean yearly relapse rate for the placebo group), the 
estimated relapse rate ratio was 0·61 (0·40–0·91; 
p=0·017). Finally, assuming a yearly relapse rate of 1·2 
for patients who withdrew because of adverse events and 
0·6 for patients who withdrew for other reasons, the 
estimated relapse ratio was 0·58 (0·37–0·90; p=0·015). 
35 reported relapses (documented and undocumented) 
in 103·6 patient-years occurred in the methyl prednisolone 
group and 92 relapses occurred in 112·0 patient-years in 
the placebo group (yearly relapse rate 0·34 vs 0·82; 
between-group diff erence 0·41, 95% CI 0·28–0·61; 
p<0·0001) in the intention-to-treat population. 21 relapses 
in the methylprednisolone group and 70 relapses in the 
placebo group were treated with glucocorticoids. Mean 
time to fi rst recorded relapse was 30·8 (SD 23·5) weeks in 
the methylprednisolone group compared with 34·9 (26·2) 
weeks in the placebo group. By Kaplan–Meier estimate, 
the probability of remaining relapse free throughout the 
trial was 76% in the methylprednisolone group compared 
with 34% in the placebo group (between-group absolute 
diff erence 42% [95% CI 26–58%]; log-rank p<0·0001). We 
also did a sensitivity analysis of the relapse-free patients 
that assumed the best scenario (no relapses in the 
dropouts) and the worst scenario (all dropouts had a 
relapse). For the best scenario, the estimated odds ratio 
would be 0·15 (95% CI 0·06–0·36; p<0·0001); for the 
worst scenario, the estimated odds ratio would be 0·48 
(0·22–1·05; p=0·064). 
To account for any interaction between baseline 
variables and treatment outcome, the yearly relapse rate 
was analysed according to EDSS score (0–2·5 points 
[eg, no or negligible disability] vs 3·0–5·5 points [eg, 
some disability]), number of relapses in the 12 months 
before randomisation (one vs two or more), ascertained 
from documentation or patient recollection, age (older or 
younger than the median age of 38·7 years for the 
intention-to-treat population), sex, and country. A 
signifi cant interaction was noted between treatment 
eff ect and baseline EDSS score (p=0·007), implying that 
no treatment eff ect was seen for patients with a baseline 
EDSS of 3 points or more. However, the overall treatment 
eff ect adjusted for baseline EDSS was signifi cant (relapse 
rate ratio 0·33, 95% CI 0·19–0·56; p<0·0001). This 
interaction eff ect could be accounted for by diff erences in 
withdrawals: more patients with low baseline EDSS 
scores withdrew in the methylprednisolone group (n=20) 
compared with patients in the placebo group (n=7). No 
other signifi cant interactions were reported. 
Figure 2 shows the Kaplan–Meier estimates of an 
increase in disability by 1 point or more on the EDSS, 
confi rmed at 24 weeks. The diff erence between groups 
was not statistically signifi cant (p=0·29), with an 
estimated probability of progression at 96 weeks of 16% 
(95% CI 6–26%) in the methylprednisolone group and 
25% (13–36%) in the placebo group (36% reduction [95% 
CI –37 to 70%]).
Table 3 shows the MSFC score and its subscales and 
change from baseline to weeks 48 and 96. MSFC score 
was calculated from the results of the paced auditory serial 
addition test, the nine-hole peg test, and the timed 25-foot 
walk test. Scores were standardised to the baseline MSFC 
score for the intention-to-treat population.23 The diff erence 
between treatments in MSFC score from baseline to week 
48 was –0·11 (95% CI –0·26 to 0·05; p=0·17), and –0·05 
(–0·22 to 0·11; p=0·52) from baseline to week 96.
 Methylprednisolone (n=66) Placebo (n=64)
0 52 23
1 7 24
2 5 11
3 2 5
4 0 0
5 0 1
Data are number of patients, ranged by number of relapses.
Table 2: Distribution of documented relapses between 0 and 96 weeks 
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MRI at baseline and at study termination (after 
96 weeks or after discontinuation of study drug) was 
done in 54 patients in the methylprednisolone group and 
56 patients in the placebo group. 34 of 55 patients who 
withdrew underwent MRI after discontinuation of the 
study drug. In the methylprednisolone group, 253 active 
lesions were recorded in 92·8 patient-years, whereas 
369 active lesions in 104·4 patient-years were noted in 
the placebo group.
The mean number of new or enlarging lesions per 
patient per year was 2·7 (95% CI 2·0–3·8) in the methyl-
prednisolone group and 3·5 (2·7–4·7) in the placebo 
group (23% reduction; relative rate ratio 0·77, 95% CI 
0·50–1·19; p=0·24). Table 4 shows the changes in 
T2-lesion volume and ormali ed brain parenchymal 
volume from baseline.
Neutralising antibodies were detected at least once in 
12 of 47 (26%) patients in the methylprednisolone group 
and in 16 of 46 (35%) patients in the placebo group. Some 
blood samples contained toxic substances (eg, bacterial 
endotoxins) or endogenous antiviral activity that 
prevented measurement of neutralising antibodies. 
Nine (23%) of 39 patients in the methylprednisolone 
group and 13 (30%) of 43 patients in the placebo group 
were positive for neutralising antibodies at 96 weeks. 
Table 5 shows the yearly relapse rate and number of new 
or enlarging T2 lesions seen on MRI in patients grouped 
according to neutralising antibody status. 
Because an unexpectedly high number of patients 
discontinued study medication, additional analyses were 
done to assess whether withdrawal of the study drug in 
these patients had aff ected the assessment of treatment 
effi  cacy. Of 18 patients who discontinued methyl-
prednisolone but completed follow-up at 96 weeks, 
15 continued with interferon beta-1a as the only 
immunomodulatory drug, two were treated with 
mitoxantrone, and one received glatiramer acetate. Of 
the nine patients in the placebo group who discontinued 
placebo but completed follow-up at 96 weeks, fi ve 
continued with interferon beta-1a as the only immuno-
modulatory drug, two were treated with mitoxantrone, 
and two received natalizumab. Mean time in the trial 
after treatment termination was 53·4 weeks (SD 37·3) in 
the methylprednisolone group and 29·4 weeks (25·7) in 
the placebo group. Post-hoc analysis showed no diff erence 
between the treatment groups for mean time to sustained 
increase in disability or number of patients with a 
sustained increase in disability in the patients who 
discontinued.
Table 6 shows adverse events according to treatment 
group. More adverse events were recorded in the 
methylprednisolone group than in the placebo group: 
18 patients (27%) assigned to methylprednisolone and two 
(3%) assigned to placebo withdrew from the study because 
of adverse events. Most adverse events in both groups were 
deemed by the investigators as possibly or probably related 
to the treatment. In particular, psychiatric symptoms, 
mainly insomnia and restlessness, and gastrointestinal 
symptoms, particularly dyspepsia, were reported more 
frequently by the methylprednisolone group than they 
were by the placebo group. Neurological symptoms were 
also reported more frequently by the methylprednisolone 
group than by the placebo group; changes in taste 
(dysgeusia and ageusia) were the most common. Osteo-
porosis was recorded as an adverse event in three patients 
in each group. Measurements of bone mineral density of 
the lumbar spine showed small changes from baseline at 
week 96: a mean reduction of 2·8% (SD 6·3%) in the 
methylprednisolone group, whereas in the placebo group 
the decline was 0·6% (5·9%). More abnormalities in the 
results of laboratory tests were recorded in the methyl-
prednisolone group than in the placebo group, but few of 
the abnormalities were judged as clinically signifi cant by 
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Figure 2: Kaplan–Meier plots of time to sustained progression of disability
Meth lprednisolone (n=49) Placebo (n=53)
MSFC
Baseline –0·02 (0·70) 0·02 (0·64)
Week 48 0·12 (0·39) 0·01 (0·42)
Week 96 0·12 (0·52) 0·06 (0·33)
Paced auditory serial addition test
Baseline 0·02 (0·97) –0·03 (1·04)
Week 48 –0·06 (0·87) 0·15 (0·63)
Week 96 0·29 (0·77) 0·24 (0·68)
Nine-hole peg test
Baseline –0·02 (0·97) 0·02 (1·04)
Week 48 0·26 (0·43) 0·01 (0·62)
Week 96 0·07 (0·54) –0·05 (0·61)
25-foot timed walking
Baseline –0·06 (1·2) 0·06 (0·74)
Week 48 0·15 (0·92) –0·13 (0·55)
Week 96 –0·01 (1·26) –0·03 (0·79)
Da a are ean (SD). MSFC=multiple sclerosis functional composi e. 
Table 3: MSFC and subscales. Baseline values and change from baseline 
to week 48 and to week 96
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the investigators: in the methylprednisolone group, fi ve 
patients had increased liver enzymes, one had leucopenia, 
and one had an increased white blood cell count. 
Serious adverse events were reported by ten patients 
(11 events). In the methylprednisolone group, one person 
was admitted to hospital owing to urosepsis and another 
was admitted because of a peritoneal infection; both 
events were deemed treatment related. One patient was 
admitted to hospital for arthroscopy of the knee, which 
was unrelated to the study drug; one had severely raised 
concentrations of liver enzymes ascribed to the interferon 
beta treatment; and another had recurrence of a cancer 
in the parotid gland, which was unrelated to the study 
drug. In the placebo group, one patient had two serious 
adverse events—a deep vein thrombosis in the right 
lower limb and an extrauterine pregnancy; both adverse 
events were deemed unrelated to the study drug. Another 
patient was admitted to hospital with dystonia that started 
before the fi rst dose of study drug and was therefore 
regarded as unrelated to treatment. One patient was 
admitted to hospital for a cholecystectomy, another was 
admitted with pyelonephritis, and another with severe 
migraines, which were deemed as unrelated to the 
treatment drug by the investigator. One patient in the 
placebo group died during the trial after admission to 
hospital with signs of pneumonia; this was not deemed 
related to the treatment by the investigator and a 
post-mortem examination was not done. 
Discussion
The fi ndings of the NORMIMS study showed that add-on 
therapy of oral methylprednisolone for 96 weeks 
in patients with relapsing-remitting multiple sclerosis 
reduced the yearly relapse rate compared with that 
of patients on placebo. Unfortunately, the enrolment 
of patients had to be terminated prematurely because of 
slow recruitment; therefore, we believe the study was 
underpowered to show the predicted 30% reduction in 
relapse rate. However, our fi ndings showed that 
methylprednisolone as an add-on therapy had a positive 
eff ect on the primary outcome measure was owing to a 
higher than expected reduction in relapse rate. 
There was no diff erence in the main secondary MRI 
outcome—new or enlarging T2 lesions—in the 
methylprednisolone group compared with the placebo 
group. The diff erence between the eff ect on relapse-related 
outcomes and on new or enlarging T2 lesions is 
intriguing, and we cannot provide a clear explanation. 
However, the converging evidence of a treatment eff ect 
of methylprednisolone was encouraging, and all 
secondary and tertiary effi  cacy measures were in favour 
of methylprednisolone, although the change in 
T2-weighted lesion volume was the only MRI measure 
that reached statistical signifi cance.
Diff erences in baseline characteristics were minor, and 
multiple regression analysis that included the baseline 
variables showed only an interaction between EDSS and 
treatment response, which could not explain the 
diff erence in treatment eff ect between methylpred-
nisolone and placebo. 
As is reported in other studies of eff ective drugs for 
multiple sclerosis, more unscheduled visits for suspected 
Methylprednisolone 
(n=54)
Placebo    
(n=56)
Diff erence (95% CI) p
T2-lesion volume (mm³) –136·6 (1468·1) 464·7 (1628·0) 601·3 (14·7 to 1188·0) 0·045
Normalised brain 
parenchymal volume (%)
–1·33 (1·23%) –1·60 (1·22%) 0·27 (–0·19 to 0·74) 0·25
Data are mean (SD), mean change from baseline (%), or diff erence (95% CI). 
Table 4: Change from baseline in T2-lesion volume and normalised brain parenchymal volume
Neutralising antibodies Yearly rate ratio p
 Negative Positive
Yearly relapse rate
Methylprednisolone 0·24 (0·16–0·38) 0·16 (0·06–0·42) 1·55 (0·15–4·56) 0·43
Placebo 0·52 (0·38–0·70) 0·88 (0·58–1·33) 0·59 (0·35–0·98) 0·04
New or enlarging T2 lesions
Methylprednisolone 2·28 (1·57–3·33) 4·03 (2·27–7·16) 0·57 (0·30–1·08) 0·08
Placebo 2·66 (1·90–3·72) 5·86 (3·66–9·37) 0·45 (0·26–0·78) 0·005
Data are mean (95% CI). 
Table 5: Yearly relapse rate and number of new or enlarging T2 lesions on MRI in patients grouped 
according to neutralising antibody status
 Methylprednisolone 
(n=66)
 Placebo 
(n=64)
Infl uenza-like symptoms 3 2
Muscle tenderness 8 4
Fever 2 4
Fatigue 4 2
Irritation or pain at injection site 2 3
Psychiatric symptoms 17 7
Infections 32 25
Gastrointestinal symptoms 14 10
Headache 5 6
Pain 9 8
Neurological symptoms* 18 12
Endocrine disturbance 8 6
Cardiovascular symptoms 6 5
Skin symptoms 8 8
Autonomic disturbance 4 ··
Sleep disturbance 17 5
Osteoporosis or osteopenia 3 3
Respiratory disturbance 4 1
Laboratory test result 
abnormalities
11 2
Other 15 8
Data are number of events. *Most commonly dysgeusia and ageusia.
Table 6: Adverse events according to treatment group
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the investigators: in the methylprednisolone group, fi ve 
patients had increased liver enzymes, one had leucopenia, 
and one had an increased white blood cell count. 
Serious adverse events were reported by ten patients 
(11 events). In the methylprednisolone group, one person 
was admitted to hospital owing to urosepsis and another 
was admitted because of a peritoneal infection; both 
events were deemed treatment related. One patient was 
admitted to hospital for arthroscopy of the knee, which 
was unrelated to the study drug; one had severely raised 
concentrations of liver enzymes ascribed to the interferon 
beta treatment; and another had recurrence of a cancer 
in the parotid gland, which was unrelated to the study 
drug. In the placebo group, one patient had two serious 
adverse events a deep vein thro bosis in the right 
lower li b and an extrauterine pregnancy; both adverse 
events were dee ed unrelated to the study drug. Another 
patient was ad itted to hospital with dystonia that started 
before the fi rst dose of study drug and was therefore 
regarded as unrelated to treat ent. One patient was 
ad itted to hospital for a cholecystecto y, another was 
ad itted with pyelonephritis, and another with severe 
igraines, which were dee ed as unrelated to the 
treat ent drug by the investigator. One patient in the 
placebo group died during the trial after ad ission to 
hospital with signs of pneu onia; this was not dee ed 
related to the treat ent by the investigator and a 
post- orte  exa ination was not done. 
Discussion
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underpowered to show the predicted 30  reduction in 
relapse rate. owever, our fi ndings showed that 
ethylprednisolone as an add-on therapy had a positive 
eff ect on the pri ary outco e easure was owing to a 
higher than expected reduction in relapse rate. 
There was no diff erence in the ain secondary RI 
outco e new or enlarging T2 lesions in the 
ethylprednisolone group co pared with the placebo 
group. The diff erence between the eff ect on relapse-related 
outco es and on new or enlarging T2 lesions is 
intriguing, and e cannot provide a clear explanation. 
o ever, the converging evidence of a treat ent eff ect 
of ethylprednisolone as encouraging, and all 
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ultiple regression analysis that included the baseline 
variables sho ed only an interaction bet een E SS and 
treat ent response, hich could not explain the 
diff erence in treat ent eff ect bet een ethylpred-
nisolone and placebo. 
s is reported in other studies of eff ective drugs for 
ultiple sclerosis, ore unscheduled visits for suspected 
Methylprednisolone 
(n=54)
Placebo    
(n=56)
Diff erence (95% CI) p
T2-lesion volume (mm³) –136·6 (1468·1) 464·7 (1628·0) 601·3 (14·7 to 1188·0) 0·045
Normalised brain 
parenchymal volume (%)
–1·33 (1·23%) –1·60 (1·22%) 0·27 (–0·19 to 0·74) 0·25
Data are mean (SD), mean change from baseline (%), or diff erence (95% CI). 
Table 4: Change from baseline in T2-lesion volume and normalised brain parenchymal volume
Neutralising antibodies Yearly rate ratio p
 Negative Positive
Yearly relapse rate
Methylprednisolone 0·24 (0·16–0·38) 0·16 (0·06–0·42) 1·55 (0·15–4·56) 0·43
Placebo 0·52 (0·38–0·70) 0·88 (0·58–1·33) 0·59 (0·35–0·98) 0·04
New or enlarging T2 lesions
Methylprednisolone 2·28 (1·57–3·33) 4·03 (2·27–7·16) 0·57 (0·30–1·08) 0·08
Placebo 2·66 (1·90–3·72) 5·86 (3·66–9·37) 0·45 (0·26–0·78) 0·005
Data are mean (95% CI). 
Table 5: Yearly relapse rate and number of new or enlarging T2 lesions on MRI in patients grouped 
according to neutralising antibody status
 Methylprednisolone 
(n=66)
 Placebo 
(n=64)
Infl uenza-like symptoms 3 2
Muscle tenderness 8 4
Fever 2 4
Fatigue 4 2
Irritation or pain at injection site 2 3
Psychiatric symptoms 17 7
Infections 32 25
Gastrointestinal symptoms 14 10
Headache 5 6
Pain 9 8
Neurological symptoms* 18 12
Endocrine disturbance 8 6
Cardiovascular symptoms 6 5
Skin symptoms 8 8
Autonomic disturbance 4 ··
Sleep disturbance 17 5
Osteoporosis or osteopenia 3 3
Respiratory disturbance 4 1
Laboratory test result 
abnormalities
11 2
Other 15 8
Data are number of events. *Most commonly dysgeusia and ageusia.
Table 6: Adverse events according to treatment group
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the investigators: in the methylprednisolone group, fi ve 
patients had increased liver enzymes, one had leucopenia, 
and one had an increased white blood cell count. 
Serious adverse events were reported by ten patients 
(11 events). In the methylprednisolone group, one person 
was admitted to hospital owing to urosepsis and another 
was admitted because of a peritoneal infection; both 
events were deemed treatment related. One patient was 
admitted to hospital for arthroscopy of the knee, which 
was unrelated to the study drug; one had severely raised 
concentrations of liver enzymes ascribed to the interferon 
beta treatment; and another had recurrence of a cancer 
in the parotid gland, which was unrelated to the study 
drug. In the placebo group, one patient had two serious 
adverse events—a deep vein thrombosis in the right 
lower limb and an extrauterine pregnancy; both adverse 
events were deemed unrelated to the study drug. Another 
patient was admitted to hospital with dystonia that started 
before the fi rst dose of study drug and was therefore 
regarded as unrelated to treatment. One patient was 
admitted to hospital for a cholecystectomy, another was 
admitted with pyelonephritis, and another with severe 
migraines, which were deemed as unrelated to the 
treatment drug by the investigator. One patient in the 
placebo group died during the trial after admission to 
hospital with signs of pneumonia; this was not deemed 
related to the treatment by the investigator and a 
post-mortem examination was not done. 
Discussion
The fi ndings of the NORMIMS study showed that add-on 
therapy of oral methylprednisolone for 96 weeks 
in patients with relapsing-remitting multiple sclerosis 
reduced the yearly relapse rate compared with that 
of patients on placebo. Unfortunately, the enrolment 
of patients had to be terminated prematurely because of 
slow recruitment; therefore, we believe the study was 
underpowered to show the predicted 30% reduction in 
relapse rate. However, our fi ndings showed that 
methylprednisolone as an add-on therapy had a positive 
eff ect on the primary outcome measure was owing to a 
higher than expected reduction in relapse rate. 
There was no diff erence in the main secondary MRI 
outcome—new or enlarging T2 lesions—in the 
methylprednisolone group compared with the placebo 
group. The diff erence between the eff ect on relapse-related 
outcomes and on new or enlarging T2 lesions is 
intriguing, and we cannot provide a clear explanation. 
However, the converging evidence of a treatment eff ect 
of methylprednisolone was encouraging, and all 
secondary and tertiary effi  cacy measures were in favour 
of methylprednisolone, although the change in 
T2-weighted lesion volume was the only MRI measure 
that reached statistical signifi cance.
Diff erences in baseline characteristics were minor, and 
multiple regression analysis that included the baseline 
variables showed only an interaction between EDSS and 
treatment response, which could not explain the 
diff erence in treatment eff ect between methylpred-
nisolone and placebo. 
As is reported in other studies of eff ective drugs for 
multiple sclerosis, more unscheduled visits for suspected 
Methylprednisolone 
(n=54)
Placebo    
(n=56)
Diff erence (95% CI) p
T2-lesion volume (mm³) –136·6 (1468·1) 464·7 (1628·0) 601·3 (14·7 to 1188·0) 0·045
Normalised brain 
parenchymal volume (%)
–1·33 (1·23%) –1·60 (1·22%) 0·27 (–0·19 to 0·74) 0·25
Data are mean (SD), mean change from baseline (%), or diff erence (95% CI). 
Table 4: Change from baseline in T2-lesion volume and normalised brain parenchymal volume
Neutralising antibodies Yearly rate ratio p
 Negative Positive
Yearly relapse rate
Methylprednisolone 0·24 (0·16–0·38) 0·16 (0·06–0·42) 1·55 (0·15–4·56) 0·43
Placebo 0·52 (0·38–0·70) 0·88 (0·58–1·33) 0·59 (0·35–0·98) 0·04
New or enlarging T2 lesions
Methylprednisolone 2·28 (1·57–3·33) 4·03 (2·27–7·16) 0·57 (0·30–1·08) 0·08
Placebo 2·66 (1·90–3·72) 5·86 (3·66–9·37) 0·45 (0·26–0·78) 0·005
Data are mean (95% CI). 
Table 5: Yearly relapse rate and number of new or enlarging T2 lesions on MRI in patients grouped 
according to neutralising antibody status
 Methylprednisolone 
(n=66)
 Placebo 
(n=64)
Infl uenza-like symptoms 3 2
Muscle tenderness 8 4
Fever 2 4
Fatigue 4 2
Irritation or pain at injection site 2 3
Psychiatric symptoms 17 7
Infections 32 25
Gastrointestinal symptoms 14 10
Headache 5 6
Pain 9 8
Neurological symptoms* 18 12
Endocrine disturbance 8 6
Cardiovascular symptoms 6 5
Skin symptoms 8 8
Autonomic disturbance 4 ··
Sleep disturbance 17 5
Osteoporosis or osteopenia 3 3
Respiratory disturbance 4 1
Laboratory test result 
abnormalities
11 2
Other 15 8
Data are number of events. *Most commonly dysgeusia and ageusia.
Table 6: Adverse events according to treatment group
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neuritis study had no brain lesions on MRI, and 
these patients had a particularly low risk for developing 
clinically defi nite multiple sclerosis.
A gime  of high-dose intravenous m thylpred i-
solone (500 mg daily for 3 consecutive days with an oral 
taper) was compared with a low-dose regimen (10 mg 
daily for 3 consecutive days with an oral taper given every 
other month for up to 2 years) in 108 patients with 
secondary-progressive multiple sclerosis.44 No diff erence 
was recorded between the two doses with respect to the 
primary outcome measure—proportion of patients with 
sustained progression (low dose 54% vs high dose 39%; 
p=0·18). However, a Kaplan–Meier analysis of time to 
sustained progression was in favour of high-dose 
methylprednisolone (p=0·04). 
The SENTINEL (safety and effi  cacy of natalizumab in 
combination with interferon beta-1a in patients with 
relapsing-remitting multiple sclerosis) study was a large, 
randomised, double-blind, placebo-controlled study of 
natalizumab as an add-on therapy to intramuscular 
interferon beta-1a versus placebo in patients who had 
breakthrough disease on interferon beta therapy.45 The 
characteristics of the patients in the SENTINEL study 
were similar to those of our population with regard to 
age, EDSS score, relapse activity, and duration of 
interferon beta therapy, whereas the proportion of men 
was lower and the mean time since onset slightly longer 
(table 7). In the natalizumab arm, the relapse rate 
reduction was 54% and the decline in the probability of 
sustained EDSS progression was 24% compared with 
placebo. These effi  cacy measures are not very diff erent 
from those reported in our study.
In the Avonex Combination Therapy (ACT) study,46,47 
bimonthly intravenous methylprednisolone (1000 mg 
daily for 3 consecutive days; n=66) was compared with 
methotrexate (20 mg daily; n=76), the combination of the 
two drugs (n=74), and placebo (n=70) as an add-on 
therapy to intramuscular interferon beta-1a (30 µg per 
week for 12 months) in patients with relapsing-remitting 
multiple sclerosis who had had a relapse during the 
previous year while on intramuscular interferon beta-1a 
or who had gadolinium-enhancing lesions seen on 
baseline MRI of the brain. Similar to the NORMIMS 
study, the ACT trial was stopped early because of slow 
recruitment: the original plan was to enrol 900 patients, 
with follow-up of 24 months, and relapse rate as the 
primary outcome;46 however, the trial was discontinued 
after 313 patients were enrolled, the study time was 
reduced to 12 months, and the primary endpoint was 
changed to the number of new or enlarging T2 lesions 
on brain MRI. In the 12-month study, 23 out of 78 patients 
(29%) in the placebo group and 23 out of 74 patients 
(31%) in the methylprednisolone group discontinued the 
study or study medication. The ACT study used a 2×2 
factorial design, which makes direct comparison of the 
treatment eff ect of methylprednisolone versus placebo 
with the eff ect in our study diffi  cult. Several of the ACT 
outcome measures favoured methylprednisolone, as 
they seem to do in our study, although the diff erences 
were not signifi cant: relapse rate ratio 0·70, 95% CI 
0·42–1·17 (p=0·17); odds ratio of change in EDSS score 
0·76, 0·47–1·22 (p=0·25); ratio of probability of 
progression 0·62, 0·26–1·48 (p=0·24); and odds ratio of 
new or enlarging T2 lesions 0·74, 0·47–1·15 (p=0·18). 
Furthermore, the ACT study was underpowered to show 
eff ects on clinical endpoints, with relative reductions of 
about 30%. Compared with our study, the most notable 
diff erences in the ACT trial were shorter study duration, 
reduced frequency of methylprednisolone administration, 
and no blinding of the intravenous methylprednisolone 
treatment.46,47 To ascertain whether the frequency of 
methylprednisolone administration aff ects relapse rate 
will require a large dose-comparison study. By 
comparison with our study population, patients in the 
ACT trial were older, had longer duration of disease, and 
had lower relapse activity in the 12 months before 
inclusion (table 7).
The methylprednisolone in combination with 
interferon beta-1a (MECOMBIN) study is a multicentre, 
double-blind, randomised, parallel-group trial of 
341 patients with relapsing-remitting multiple sclerosis 
who are treatment naive; the fi ndings of this trial are as 
yet unpublished but have been presented as an abstract 
at the 2009 American Academy of Neurology annual 
meeting.48 Patients were randomly assigned to either 
methylprednisolone (500 mg per day for 3 consecutive 
days every month for 3–4 years; n=172) or placebo (n=169) 
as add-on treatment to intramuscular interferon beta-1a. 
The yearly recorded relapse rate was 0·205 in the 
methylprednisolone group and 0·333 in the placebo 
group (relative reduction 38%; p<0·01). Time to sustained 
progression did not diff er between treatment groups 
(hazard ratio 0·8; p=0·33). Mean MSFC score rose by 
0·06 in the methylprednisolone group, but decreased by 
NORMIMS
(n=66)
ACT
(n=74)
SENTINEL
(n=589)
Baseline demographics
Age (years) 37·8 42·9 38·8
Proportion men 44% 28% 25%
Time since onset of symptoms (years) 5·3* 10·7 7·0*
EDSS score 2·5 2·8 2·4
Relapses during previous 12 months 1·6 1·3 1·4
Duration of interferon beta-1a treatment (years) 2·8 2·8 2·8
Effi  cacy measures
Reduction in relapse rate 62% (p<0·0001) 30% 55% (p<0·001)
Reduction in progression rate 38% (p=0·29) ·· 24% (p=0·02)
Reduction in new or enlarging T2 lesions 23% (p=0·24) ·· 83% (p<0·001)
Data are mean, unless otherwise indicated. ··=not done. *Median.
Table 7: Comparison of methylprednisolone add-on groups in NORMIMS and ACT trials and the 
natalizumab add-on group in the SENTINEL trial
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anticipated a dropout rate of 15%; hence, a cohort of 
300 patients was planned for the trial. However, enrolment 
was discontinued prematurely after 130 patients had been 
randomised, owing to slow recruitment.
All statistical analyses were approved by the NORMIMS 
study steering committee before unmasking. The 
primary analyses were intention to treat, which included 
all randomised patients, whereas patients who completed 
96 weeks of treatment and assessments without any 
major protocol deviations were included in the 
per-protocol analyses. We assessed baseline comparability 
with a two-way analysis-of-variance model and categorical 
variables with χ² tests. We analysed the primary endpoint 
(mean yearly relapse rate) with a Poisson regression 
model; to estimate the eff ect of baseline variables on the 
primary outcome we used multiple Poisson regression 
analysis. If the EDSS score was missing for a visit, we 
deemed disability as not increased for that visit compared 
with the previous visit. The probability of remaining 
relapse free and the increase in disability measured with 
the EDSS were estimated by Kaplan–Meier survival 
analysis, and we assessed the diff erences in the survival 
curves with the log-rank test. We analysed the MSFC 
with the t distribution at every visit to the evaluating 
neurologist. MSFC scores were standardised to the mean 
baseline MSFC value for the intention-to-treat 
population.23 We used Poisson regression to evaluate the 
number of active lesions on MRI. The occurrence of 
neutralising antibodies was analysed with logistic 
regression and proportional odds models, both with and 
without adjustment for baseline status. For sensitivity 
analyses of the primary outcome measure, we used the 
Poisson regression model for multiple imputations of 
relapses for early dropouts. We used 200 imputations for 
every missing observation and combined the results in 
accordance with standard methods.24 All statistical tests 
were two-sided (α=0·05). All models were checked for 
assumption violations. Poisson models were tested for 
overdispersion and underdispersion and, if necessary, 
adjusted with quasi-likelihood estimates.25 We did all 
calculations with SAS version 9.1.3 (SAS Institute, Cary, 
NC, USA).
This trial is registered, number ISRCTN16202527. 
Role of the funding source 
Data management and analyses were done by an 
independent contract research organisation (Smerud 
Medical Research International AS, Oslo, Norway). The 
sponsor of the study had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
130 patients were randomly assigned to add-on therapy: 
66 to oral methylprednisolone and 64 to placebo (fi gure 1). 
Table 1 shows baseline demographics and clinical 
characteristics. 
The number of scheduled visits was similar between 
treatment groups (380 in the methylprednisolone group 
vs 382 in the placebo group), whereas more unscheduled 
visits were made for suspected relapses by patients in 
the placebo group (n=79) than by patients in the 
methylprednisolone group (n=51). 75 patients completed 
follow-up and 55 patients discontinued study medication 
prematurely, but 27 of the patients who withdrew did so 
after week 96; therefore, 102 patients completed 
 Methylprednisolone 
(n=66)
Placebo (n=64)
Age (years) 37·8 (7·4) [39·2] 39·5 (7·8) [38·5] 
Men 29 (44%) 21 (33%)
Time since onset of symptoms (years) 6·9 (5·1) [5·3] 8·5 (5·9) [7·0] 
EDSS score 2·5 (1·3) [2·5] 2·9 (1·4) [3·0] 
Number of relapses within previous year 1·6 (0·9) [1·0] 1·5 (1·0) [1·0] 
Relapses in previous year
1 41 (62%) 45 (70%)
2 15 (23%) 13 (20%)
≥3 10 (15%) 6 (9%)
Duration of interferon beta-1a treatment (years) 2·8 (1·8) [2·3] 3·4 (2·1) [2·8]
T2 lesion volume (mm³) 7671·9 (8705·3) [3888·0]* 11 507·7 (14 538·0) [6054·0]† 
Brain parenchymal volume (cm³) 1184·1 (127·5) [1189·0]‡ 1166·1 (142·4) [1140·5]§ 
Number positive for neutralising antibodies 12/47 (26%) 16/46 (35%)
Data are mean (SD), [median], or number of patients (%). EDSS=expanded disability status scale. *n=56. †n=54. 
‡=55. §n=52. 
Table 1: Baseline demographics and clinical characteristics 
66 randomly assigned to interferon
beta-1a and methylprednisolone
(ITT population)
17 withdrew before 96 weeks
7 had adverse events
3 due to no efficacy
6 for personal reasons
1 for other reason
18 discontinued therapy but 
completed 96 weeks of 
follow-up
11 had adverse events
1 due to no efficacy
4 for personal reasons
2 for other reasons
49 completed at least 96 weeks of
follow-up
53 completed at least 96 weeks of
follow-up
9 discontinued therapy but 
completed 96 weeks of 
follow-up
5 due to no efficacy
1 for personal reasons
3 for other reasons
11 withdrew before 96 weeks
2 had adverse events
4 due to no efficacy
1 for personal reasons
1 died
3 for other reasons
64 randomly assigned to interferon
beta-1a and placebo
(ITT population)
130 patients enrolled
Figure 1: Trial profi le  
ITT=intention to treat.
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MRI at baseline and at study termination (after 
96 weeks or after discontinuation of study drug) was 
done in 54 patients in the methylprednisolone group and 
56 patients in the placebo group. 34 of 55 patients who 
withdrew underwent MRI after discontinuation of the 
study drug. In the methylprednisolone group, 253 active 
lesions were recorded in 92·8 patient-years, whereas 
369 active lesions in 104·4 patient-years were noted in 
the placebo group.
The mean number of new or enlarging lesions per 
patient per year was 2·7 (95% CI 2·0–3·8) in the methyl-
prednisolone group and 3·5 (2·7–4·7) in the placebo 
group (23% reduction; relative rate ratio 0·77, 95% CI 
0·50–1·19; p=0·24). Table 4 shows the changes in 
T2-lesion volume and normalised brain parenchymal 
volume from baseline.
Neutralising antibodies were detected at least once in 
12 of 47 (26%) patients in the methylprednisolone group 
and in 16 of 46 (35%) patients in the placebo group. Some 
blood samples contained toxic substances (eg, bacterial 
endotoxins) or endogenous antiviral activity that 
prevented measurement of neutralising antibodies. 
Nine (23%) of 39 patients in the methylprednisolone 
group and 13 (30%) of 43 patients in the placebo group 
were positive for neutralising antibodies at 96 weeks. 
Table 5 shows the yearly relapse rate and number of new 
or enlarging T2 lesions seen on MRI in patients grouped 
according to neutralising antibody status. 
Because an unexpectedly high number of patients 
discontinued study medication, additional analyses were 
done to assess whether withdrawal of the study drug in 
these patients had aff ected the assessment of treat ent 
effi  cacy. Of 18 atients who discontin ed methyl-
prednisolone t completed follow-up at 96 weeks, 
15 continued with interferon beta-1a as the only 
immunomodulatory drug, two were treated with 
mitoxantrone, and one received glatiramer acetate. Of 
the nine patients in the placebo group who discontinued 
placebo but completed follow-up at 96 weeks, fi ve 
continued with interferon beta-1a as the only immuno-
modulatory drug, two were treated with mitoxantrone, 
and two received natalizumab. Mean time in the trial 
after treatment termination was 53·4 weeks (SD 37·3) in 
the methylprednisolone group and 29·4 weeks (25·7) in 
the placebo group. Post-hoc analysis showed no diff erence 
between the treatment groups for mean time to sustained 
increase in disability or number of patients with a 
sustained increase in disability in the patients who 
discontinued.
Table 6 shows adverse events according to treatment 
group. More adverse events were recorded in the 
methylprednisolone group than in the placebo group: 
18 patients (27%) assigned to methylprednisolone and two 
(3%) assigned to placebo withdrew from the study because 
of adverse events. Most adverse events in both groups were 
deemed by the investigators as possibly or probably related 
to the treatment. In particular, psychiatric symptoms, 
mainly insomnia and restlessness, and gastrointestinal 
symptoms, particularly dyspepsia, were reported more 
frequently by the methylprednisolone group than they 
were by the placebo group. Neurological symptoms were 
also reported more frequently by the methylprednisolone 
group than by the placebo group; changes in taste 
(dysgeusia and ageusia) were the most common. Osteo-
porosis was recorded as an adverse event in three patients 
in each group. Measurements of bone mineral density of 
the lumbar spine showed small changes from baseline at 
week 96: a mean reduction of 2·8% (SD 6·3%) in the 
methylprednisolone group, whereas in the placebo group 
the decline was 0·6% (5·9%). More abnormalities in the 
results of laboratory tests were recorded in the methyl-
prednisolone group than in the placebo group, but few of 
the abnormalities were judged as clinically signifi cant by 
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Figure 2: Kaplan–Meier plots of time to sustained progression of disability
Methylprednisolone (n=49) Placebo (n=53)
MSFC
Baseline –0·02 (0·70) 0·02 (0·64)
Week 48 0·12 (0·39) 0·01 (0·42)
Week 96 0·12 (0·52) 0·06 (0·33)
Paced auditory serial addition test
Baseline 0·02 (0·97) –0·03 (1·04)
Week 48 –0·06 (0·87) 0·15 (0·63)
Week 96 0·29 (0·77) 0·24 (0·68)
Nine-hole peg test
Baseline –0·02 (0·97) 0·02 (1·04)
Week 48 0·26 (0·43) 0·01 (0·62)
Week 96 0·07 (0·54) –0·05 (0·61)
25-foot timed walking
Baseline –0·06 (1·2) 0·06 (0·74)
Week 48 0·15 (0·92) –0·13 (0·55)
Week 96 –0·01 (1·26) –0·03 (0·79)
Data are mean (SD). MSFC=multiple sclerosis functional composite. 
Table 3: MSFC and subscales. Baseline values and change from baseline 
to week 48 and to week 96
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